Literature DB >> 33154956

Prognostic Nomograms for Patients with Hepatocellular Carcinoma After Curative Hepatectomy, with a Focus on Recurrence Timing and Post-Recurrence Management.

Wei Xu1, Fei Liu1, Xianbo Shen1, Ruineng Li1.   

Abstract

BACKGROUND: Prognoses of patients with hepatocellular carcinoma (HCC) after curative hepatectomy remain unsatisfactory because of the high incidence of postoperative recurrence. Published predictive systems focus on pre-resection oncological characteristics, ignoring post-recurrence factors.
PURPOSE: This study aimed to develop prognostic nomograms for 3- and 5-year overall survival (OS) of patients with HCC after curative hepatectomy, focusing on potentially influential post-recurrence factors. PATIENTS AND METHODS: Clinicopathological and postoperative follow-up data were extracted from 494 patients with HCC who underwent curative hepatectomy between January 2012 and June 2019. Early recurrence (ER) and late recurrence (LR) were defined as recurrence at ≤2 and >2 years, respectively, after curative hepatectomy. Nomograms for the prediction of 3- and 5-year OS were established based on multivariate analysis. The areas under time-dependent receiver operating characteristic curves (AUCs) for the nomograms were calculated independently to verify predictive accuracy. The nomograms were internally validated based on 2000 bootstrap resampling of 75% of the original data.
RESULTS: In total, 494 patients with HCC who underwent curative hepatectomy met the eligibility criteria. Cox proportional hazard regression analysis identified factors potentially influencing 3- and 5-year OS. Multivariate analysis indicated that patient age, Hong Kong Liver Cancer stage, γ-glutamyl transferase (γ-GGT) level, METAVIR inflammation activity grade, ER and post-recurrence treatment modality were influencing factors for 3-year OS (AUC, 0.891; 95% CI, 0.8364-0.9447). γ-GGT > 60 U/L, hepatectomy extent, LR and post-recurrence treatment modality were influencing factors for 5-year OS (AUC, 0.864; 95% CI, 0.8041-0.9237). Calibration plots showed satisfactory concordance between the predicted and actual observation cohorts.
CONCLUSION: We propose new prognostic nomograms for OS prediction with a focus on the differentiation of recurrence timing and post-recurrence management. These nomograms overcome the shortcomings of previous predictive nomograms and significantly improve predictive accuracy.
© 2020 Xu et al.

Entities:  

Keywords:  hepatectomy; hepatocellular carcinoma; nomogram; overall survival; post-recurrence management

Year:  2020        PMID: 33154956      PMCID: PMC7606947          DOI: 10.2147/JHC.S271498

Source DB:  PubMed          Journal:  J Hepatocell Carcinoma        ISSN: 2253-5969


  58 in total

1.  Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies.

Authors:  Ronnie T P Poon
Journal:  Ann Surg Oncol       Date:  2009-02-04       Impact factor: 5.344

Review 2.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; María Reig; Jordi Bruix
Journal:  Lancet       Date:  2018-01-05       Impact factor: 79.321

3.  A novel and validated prognostic nomogram based on liver fibrosis and tumor burden for patients with hepatocellular carcinoma after curative resection.

Authors:  Jin-Long Huang; Yi-Peng Fu; Chu-Yu Jing; Yong Yi; Jian Sun; Wei Gan; Zhu-Feng Lu; Jian Zhou; Jia Fan; Shuang-Jian Qiu
Journal:  J Surg Oncol       Date:  2017-11-22       Impact factor: 3.454

4.  A laboratory marker, FIB-4 index, as a predictor for long-term outcomes of hepatocellular carcinoma patients after curative hepatic resection.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Yuji Kaneoka; Atsuyuki Maeda
Journal:  Surgery       Date:  2015-02-20       Impact factor: 3.982

5.  Assessment of complications after pancreatic surgery: A novel grading system applied to 633 patients undergoing pancreaticoduodenectomy.

Authors:  Michelle L DeOliveira; Jordan M Winter; Markus Schafer; Steven C Cunningham; John L Cameron; Charles J Yeo; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2006-12       Impact factor: 12.969

6.  Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis.

Authors:  Parissa Tabrizian; Ghalib Jibara; Brian Shrager; Myron Schwartz; Sasan Roayaie
Journal:  Ann Surg       Date:  2015-05       Impact factor: 12.969

7.  Nomogram to Predict Survival of Patients With Recurrence of Hepatocellular Carcinoma After Surgery.

Authors:  Wei He; Baogang Peng; Yunqiang Tang; Junpin Yang; Yun Zheng; Jiliang Qiu; Ruhai Zou; Jingxian Shen; Binkui Li; Yunfei Yuan
Journal:  Clin Gastroenterol Hepatol       Date:  2017-12-12       Impact factor: 11.382

8.  Prognostic nomogram for patients with hepatocellular carcinoma underwent adjuvant transarterial chemoembolization following curative resection.

Authors:  Chu-Yu Jing; Yi-Peng Fu; Su-Su Zheng; Yong Yi; Hu-Jia Shen; Jin-Long Huang; Xin Xu; Jia-Jia Lin; Jian Zhou; Jia Fan; Zheng-Gang Ren; Shuang-Jian Qiu; Bo-Heng Zhang
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

9.  Hypofractionated radiotherapy as a salvage treatment for recurrent hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multi-center analysis.

Authors:  Jinrong Lou; Yong Li; Kangning Liang; Yutian Guo; Changlong Song; Lei Chen; Lifang Wang; Fei Wang; Li Zhang; Xia Chen; Xiangdong Xu; Mianshun Pan
Journal:  BMC Cancer       Date:  2019-07-05       Impact factor: 4.430

10.  Establishment and Validation of SSCLIP Scoring System to Estimate Survival in Hepatocellular Carcinoma Patients Who Received Curative Liver Resection.

Authors:  Sha Huang; Gui-Qian Huang; Gui-Qi Zhu; Wen-Yue Liu; Jie You; Ke-Qing Shi; Xiao-Bo Wang; Han-Yang Che; Guo-Liang Chen; Jian-Feng Fang; Yi Zhou; Meng-Tao Zhou; Yong-Ping Chen; Martin Braddock; Ming-Hua Zheng
Journal:  PLoS One       Date:  2015-06-09       Impact factor: 3.240

View more
  1 in total

1.  Rethinking Liver Fibrosis Staging in Patients with Hepatocellular Carcinoma: New Insights from a Large Two-Center Cohort Study.

Authors:  Wei Xu; Bolun Li; Zhanwei Yang; Jingdong Li; Fei Liu; Yu Liu
Journal:  J Hepatocell Carcinoma       Date:  2022-08-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.